Related Experiment Videos
Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up
N M Lakkis1, S F Nagueh, J K Dunn
1Baylor College of Medicine, Department of Medicine, Houston, Texas, USA.
Insights
Nonsurgical septal reduction therapy effectively treats symptomatic hypertrophic obstructive cardiomyopathy, showing sustained symptom relief and improved exercise capacity one year post-procedure. This minimally invasive approach offers a promising treatment for patients with this condition.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Left ventricular outflow tract obstruction significantly impacts symptoms in hypertrophic obstructive cardiomyopathy (HOCM).
- Nonsurgical septal reduction is an emerging therapy demonstrating efficacy in reducing left ventricular outflow tract gradients and alleviating symptoms.
Purpose of the Study:
- To assess the one-year clinical outcomes of the initial 50 patients who underwent nonsurgical septal reduction for symptomatic HOCM.
- To evaluate the long-term effectiveness of this novel therapeutic approach.
Main Methods:
- A cohort of 50 HOCM patients undergoing nonsurgical septal reduction were followed for one year.
- Data collected included clinical history, physical examinations, echocardiography with Doppler, and exercise treadmill testing.
Main Results:
- All patients experienced symptom resolution, with 94% improving from NYHA class III/IV to asymptomatic at one year (p < 0.001).
- Exercise duration increased significantly (136s, p < 0.021), and resting/provoked LVOT gradients markedly decreased (p < 0.01).
- Septal thickness reduced, and systolic function was preserved, with minimal medication use at follow-up.
Conclusions:
- Nonsurgical septal reduction therapy provides a durable and effective treatment for symptomatic HOCM patients.
- The positive outcomes observed at one year support its role in managing HOCM.
Objective:
The objective of this study is to evaluate the one-year outcome of the first 50 patients who underwent nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy at our institution.
Background:
Left ventricular outflow tract obstruction is an important determinant of clinical symptoms in patients with hypertrophic obstructive cardiomyopathy. Nonsurgical septal reduction is a new therapy that has been shown to result in left ventricular outflow tract gradient reduction and resolution of symptoms immediately after the procedure and on midterm follow-up.
Methods:
Fifty patients with hypertrophic obstructive cardiomyopathy who underwent nonsurgical septal reduction at our institution and completed 1-year follow-up are described. Complete history, physical examination, two-dimensional echocardiography with Doppler and exercise treadmill testing have been analyzed.
Results:
The mean age of the study group was 53 +/- 17 years. All patients had refractory symptoms before enrollment. Ninety-four percent had class III or IV New York Heart Association class symptoms at baseline compared to none at 1 year (p < 0.001). The exercise duration increased by 136 s at 1 year (p < 0.021). Only 20% of patients were either receiving beta-blockers or calcium-channel blockers on follow-up. The resting left ventricular outflow tract gradient decreased from 74 +/- 23 mm Hg to 6 +/- 18 mm Hg (p < 0.01) and from 84 +/- 28 mm Hg to 30 +/- 33 mm Hg (p < 0.01) in patients with dobutamine-provoked gradient at one year. These changes are associated with decreased septal thickness and preserved systolic function.
Conclusion:
Nonsurgical septal reduction therapy is an effective therapy for symptomatic patients with hypertrophic obstructive cardiomyopathy with persistence of the favorable outcome up to one year after the procedure.